Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 69   

Articles published

BMY 64.60 -4.55 (-6.58%)
price chart
BBDO, CDM Said to Win Big Bristol-Myers Squibb Brand
Omnicom agencies BBDO New York and The CDM Group have been given U.S. creative lead responsibilities for Bristol-Myers Squibb's Abilify antidepressant drug, sources said. The brand, which had been at Digitas Health, spent $133.7 million in U.S. ...
Bristol-Myers to buy Amylin for about $5.3 billion
NEW YORK Bristol-Myers Squibb Co will buy biotechnology company Amylin Pharmaceuticals Inc for about $5.3 billion in cash, helping Bristol-Myers extend its portfolio of diabetes treatments with the addition of drugs Byetta and Bydureon.
Bristol Will Buy Diabetes Drug Maker  Wall Street Journal
Bristol-Myers outbids Big Pharma pack and nabs Amylin for $5.3B  FierceBiotech
Bristol-Myers Squibb - Abilify
And finally... There is Bristol-Myers ($BMY) and its bad behavior. Its 2007 settlement covered a number of violations, such as gaming the system to jack up prices on Serzone.
Bristol-Myers Squibb and Pfizer Receive Complete Response Letter from U.S. ...
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced that the U.S.
FDA delays approval of new blood thinner  MarketWatch
Dying man fights to get experimental drug from Bristol-Myers Squibb
The company empathizes with patients who have limited treatment options, said spokeswoman Sonia Choi in a statement Sunday.
Terminally ill patients should have access to last-chance therapies
But Bristol-Myers Squibb has denied the request, saying it has a responsibility to protect patient safety in the research and development of its medicines.
Interim results from Bristol-Myers Squibb's BMS-936558 Phase 1 study on ...
Bristol-Myers Squibb Company (NYSE: BMY) today announced interim results from the expanded Phase 1 dose-ranging study 003 (n=296) of its investigational anti-PD-1 immunotherapy (BMS-936558), which showed clinical activity in patients with ...
Medivir, Bristol-Myers Squibb to initiate TMC435 and daclatasvir phase II ...
Medivir AB (OMX:MVIR), the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that a phase II combination study with the investigational compound TMC435 and Bristol-Myers ...
Legalize pure ecstasy and sell it like alcohol, BC health chief says
In this occasional feature, the National Post tells you everything you need to know about a complicated issue. Today, Tristin Hopper looks at B.C.
Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 ...
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL� (dasatinib) in Philadelphia ...